TAVI-First Strategy Proves Noninferior to PCI-First Approach in Aortic Stenosis Trial

Key Clinical Takeaways:

• A TAVI-first strategy demonstrated noninferiority regarding primary clinical endpoints at one year compared to conventional PCI-first sequencing.
• The randomized open-label trial evaluated 986 patients across 48 medical centers in Austria, France, Germany, Italy, the Netherlands, and Switzerland.
• Fewer patients in the TAVI-first arm ultimately underwent percutaneous coronary intervention, as clinical assessments regarding coronary necessity frequently evolved after valve treatment.

Evaluating the optimal sequencing of interventions for individuals presenting with narrowed aortic valves and diseased coronary arteries has historically relied on operator preference rather than high-grade randomized data. Professor Barbara Elisabeth Stähli from the University Hospital Zurich explained that approximately half of all patients undergoing transcatheter aortic valve implantation also experience coronary artery disease, with 10% to 20% requiring percutaneous coronary intervention. Clinical practice traditionally favored performing percutaneous interventions first to manage immediate ischemic risks before addressing valve pathology.

To rigorously test this standard of care, researchers designed an open-label, randomized, noninferiority trial across 48 clinical centers in six European nations. The trial enrolled 986 participants with a mean age of 82 years, where 34% of the cohort identified as women. Eligible candidates were evaluated by multidisciplinary heart teams and randomized on a 1:1 basis to receive either transcatheter aortic valve implantation followed by angiography-guided percutaneous coronary intervention, or the inverse sequence, with both procedures executed within 1 to 45 days of each other.

The primary endpoint measured at one year comprised a composite incidence of all-cause death, nonfatal myocardial infarction, ischaemia-driven revascularisation, valve-, procedure-, or heart failure-related rehospitalisation, alongside life-threatening, disabling, or major bleeding. Results established that this primary endpoint occurred in 22.2% of the TAVI-first cohort compared with 24.2% in the PCI-first cohort. The risk difference of -2.0 percentage points with a 95% confidence interval ranging from -7.4 to 3.4 satisfied the statistical threshold for noninferiority, yielding a p-value of less than 0.001.

Secondary outcomes yielded notable mechanical and pharmacological insights. Investigators observed that life-threatening, disabling, or major bleeding events occurred less frequently in the group receiving valve replacement first, reported at 6.6% compared to 9.7% in the alternative group. Professor Stähli noted that access to coronary arteries remained unimpaired following valve implantation. Instead, once the aortic valve pathology was successfully treated, the clinical calculus regarding whether subsequent percutaneous intervention remained mandatory shifted, resulting in fewer overall interventions in the TAVI-first group.

Future investigations will likely focus on subgroup analyses examining long-term structural valve durability and antiplatelet optimization schedules. As multidisciplinary heart teams digest these findings, clinical practice will increasingly pivot toward patient-specific anatomical and physiological considerations rather than rigid procedural sequencing.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*